Evommune

Evommune, Inc. (Nasdaq: EVMN) is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California, discovering and developing therapies that target the key drivers of chronic inflammatory disease. Founded in 2020 by the team behind Dermira, the company applies a human tissue-based translational approach to immunology and is advancing a clinical pipeline that includes EVO756, an oral small-molecule MRGPRX2 antagonist in Phase 2b development for chronic spontaneous urticaria and migraine prophylaxis, and an IL-18 binding protein fusion program licensed from AprilBio. Evommune publishes no developer program, no public API and no machine-readable API contract; its public web presence is a WordPress marketing site plus a hosted investor-relations portal.

Evommune is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Immunology.

🌐 Visit website 📡 Source on GitHub
11.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologyPharmaceuticalsLife SciencesImmunologyDrug DevelopmentClinical TrialsHealthcare

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 11.1/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Commercial Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.9 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/evommune: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Evommune Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Contact
Contact
 PressReleases
PressReleases

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 5

The organization behind the API

Website
Website
 About
About
 InvestorRelations
InvestorRelations
 Careers
Careers
 LinkedIn
LinkedIn

Other 3

Properties that don't map to a standard resource type

Pipeline
Pipeline
 Publications
Publications
 SecondaryMarket
SecondaryMarket

Source (apis.yml)

apis.yml Raw ↑ 
aid: evommune
name: Evommune
description: 'Evommune, Inc. (Nasdaq: EVMN) is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California,
  discovering and developing therapies that target the key drivers of chronic inflammatory disease. Founded in 2020 by the
  team behind Dermira, the company applies a human tissue-based translational approach to immunology and is advancing a clinical
  pipeline that includes EVO756, an oral small-molecule MRGPRX2 antagonist in Phase 2b development for chronic spontaneous
  urticaria and migraine prophylaxis, and an IL-18 binding protein fusion program licensed from AprilBio. Evommune publishes
  no developer program, no public API and no machine-readable API contract; its public web presence is a WordPress marketing
  site plus a hosted investor-relations portal.'
image: https://www.evommune.com/wp-content/uploads/2023/12/Evommune-blue-logo.svg
url: https://raw.githubusercontent.com/api-evangelist/evommune/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: no-api-surface
specificationVersion: '0.20'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Immunology
- Drug Development
- Clinical Trials
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.evommune.com/
- type: About
  url: https://www.evommune.com/about-us/
- type: Contact
  url: https://www.evommune.com/contact/
- type: PrivacyPolicy
  url: https://www.evommune.com/wp-content/uploads/2023/12/Evommune_privacy-statement_for_website.pdf
- type: TermsOfService
  url: https://www.evommune.com/wp-content/uploads/2023/12/Evommune_privacy-statement_for_website.pdf
- type: InvestorRelations
  url: https://ir.evommune.com/
- type: PressReleases
  url: https://ir.evommune.com/news-events/press-releases
- type: Careers
  url: https://www.evommune.com/job-openings/
- type: LinkedIn
  url: https://www.linkedin.com/company/evommune/
- type: Pipeline
  url: https://www.evommune.com/development-pipeline/
- type: Publications
  url: https://www.evommune.com/publications-posters/
- type: DomainSecurity
  url: security/evommune-domain-security.yml
- type: LLMsTxt
  url: llms/evommune-llms.txt
- type: SecondaryMarket
  url: https://forgeglobal.com/evommune_stock/
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: 'Evommune is a clinical-stage biopharmaceutical company (Nasdaq: EVMN) whose entire public surface is a WordPress
    marketing site and a hosted investor-relations portal — there is no developer section, no GitHub organization, no package
    on any registry, and every OpenAPI/GraphQL/MCP/agent-card path probed on both hosts returned 404; the only HTTP 200 API-shaped
    response is the stock WordPress REST API at /wp-json/, which is default CMS infrastructure rather than a product Evommune
    publishes.'
  evidence:
  - url: https://www.evommune.com/openapi.json
    status: 404
  - url: https://www.evommune.com/.well-known/agent-card.json
    status: 404
  - url: https://ir.evommune.com/llms.txt
    status: 404
  - url: https://api.github.com/orgs/evommune
    status: 404
  - url: https://www.evommune.com/wp-json/
    status: 200
  checked: '2026-08-12'